Brief: Landos Biopharma And LianBio Collaborate To Develop And Commercialize Omilancor And NX-13 In Greater China And Select Asian Markets

Landos Biopharma

17/05/2021 12:19

May 17 (Reuters) - Landos Biopharma Inc  LABP.O :
    * LANDOS BIOPHARMA AND LIANBIO ANNOUNCE EXCLUSIVE
COLLABORATION
AND LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE OMILANCOR AND
NX-13 IN GREATER CHINA AND SELECT ASIAN MARKETS
    * LANDOS BIOPHARMA INC - LIANBIO WILL RECEIVE EXCLUSIVE
RIGHTS TO
DEVELOP AND COMMERCIALIZE OMILANCOR AND NX-13 IN GREATER CHINA,
OTHER COUNTRIES
    * LANDOS BIOPHARMA  - LANDOS WILL RECEIVE UPFRONT CASH
PAYMENT OF
$18 MILLION & ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO
$200 MILLION
    * LANDOS BIOPHARMA INC - LIANBIO WILL FUND DEVELOPMENT AND
COMMERCIALIZATION EXPENSES IN COLLABORATION TERRITORY
    * LANDOS BIOPHARMA INC - LANDOS WILL CONTINUE TO FUND ALL
DEVELOPMENT AND COMMERCIALIZATION EXPENSES IN ALL OTHER
GEOGRAPHIES

Source text for Eikon:  ID:nGNX7kGgfL 
Further company coverage:  LABP.O 

 ((Reuters.Briefs@thomsonreuters.com;))